BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a strong partnership with Ayrmid Pharma and reduced operating costs, the company faces risks such as slow APHEXDA adoption and a significant net loss. The Q&A revealed cautious optimism with positive feedback on ASCO data but uncertainty around asset acquisition and study timelines. The neutral rating reflects balanced prospects, with financial sustainability dependent on future milestones.
Key Financial Performance
Total revenues for Q2 2025 $0.3 million, reflecting royalties paid by Ayrmid from the commercialization of APHEXDA in stem cell mobilization in the U.S. This is not comparable to Q2 2024 due to the Ayrmid transaction in November 2024.
Cost of revenues for Q2 2025 Immaterial compared to $0.9 million for Q2 2024. The change is due to the Ayrmid transaction, which shifted direct commercial sales away from BioLineRx.
Research and development expenses for Q2 2025 $2.3 million, a slight increase from $2.2 million in Q2 2024. The increase is due to one-time costs associated with the PDAC study at Columbia University, offset by lower expenses related to motixafortide and reduced payroll and share-based compensation.
Sales and marketing expenses for Q2 2025 $0 compared to $6.4 million in Q2 2024. The decrease is due to the shutdown of U.S. commercial operations following the Ayrmid transaction.
General and administrative expenses for Q2 2025 $0.2 million compared to $1.6 million in Q2 2024. The decrease is due to the reversal of a provision for doubtful accounts, reduced payroll and share-based compensation, and other small decreases in general expenses.
Net loss for Q2 2025 $3.9 million compared to net income of $0.5 million in Q2 2024. The change is attributed to the restructuring and operational changes following the Ayrmid transaction.
Cash, cash equivalents, and short-term bank deposits as of June 30, 2025 $28.2 million, sufficient to fund operations as currently planned into the first half of 2027. This represents an extension of the cash runway compared to previous guidance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
APHEXDA: Generated $1.7 million in sales in Q2 2025, resulting in $0.3 million of royalty revenues to BioLineRx. It is being studied in two Phase I trials for sickle cell disease and has potential for broader clinical utility.
Motixafortide: Continues development for pancreatic cancer (PDAC) in a Phase IIb trial. Interim analysis planned for 40% progression-free survival events. Promising data from pilot studies show improved response rates and progression-free survival compared to historical data.
Ayrmid Pharma Agreement: Exclusive out-licensing agreement for APHEXDA covering all indications except solid tumors and all territories except Asia. Includes upfront payment, commercial milestones, and royalties.
Restructuring: Implemented a broad restructuring, including shutting down U.S. operations and reducing operating cash burn by over 70%. Cash runway extended to the first half of 2027.
Pipeline Expansion: Actively evaluating early-stage oncology and rare disease assets for pipeline expansion. Targeting a transaction announcement in 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to many risks and uncertainties, which could materially impact actual results. This includes risks related to regulatory approvals and compliance.
Pipeline Expansion Challenges: The company is actively searching for early-stage assets in oncology and rare diseases, but the due diligence process is lengthy and intensive, which could delay pipeline expansion.
Clinical Trial Risks: Ongoing trials, such as the Phase IIb PDAC trial, are critical for the company's future. However, trial outcomes are uncertain, and negative results could significantly impact the company's strategic objectives.
Financial Risks: The company reported a net loss of $3.9 million for Q2 2025. While cash reserves are sufficient until the first half of 2027, financial sustainability depends on successful milestones and royalties.
Operational Risks: The company underwent a 70% reduction in operating cash burn and shut down U.S. operations, which could impact its ability to scale or respond to market opportunities.
Market Adoption Risks: APHEXDA's adoption is still in early stages, with $1.7 million in sales generating only $0.3 million in royalties. Slow adoption could impact revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Expansion: The company is actively evaluating early-stage clinical and preclinical assets in oncology and rare diseases, targeting a transaction by the end of the year to expand its pipeline.
Motixafortide in Sickle Cell Disease: Data from two investigator-sponsored Phase I trials evaluating motixafortide for mobilization of CD34-positive hematopoietic stem cells in sickle cell disease are expected in the second half of 2025.
Motixafortide in Pancreatic Cancer: The ongoing randomized Phase IIb PDAC trial, CheMo4METPANC, is evaluating motixafortide in combination with other treatments. Interim analysis is planned upon observing 40% of progression-free survival events, with results potentially serving as a significant value inflection point.
APHEXDA Commercialization: The company expects meaningful growth in APHEXDA adoption as treatment protocols are updated to reflect its availability for multiple myeloma and sickle cell disease.
Financial Outlook: The company has cash and equivalents of $28.2 million, sufficient to fund operations into the first half of 2027, extending its previous guidance of the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does Regeneron have any options or rights of first refusal regarding the CheMo4METPANC study?
A:No, Regeneron does not have any options or rights of first refusal. It is a clinical collaboration where both sides have access to the data, but no additional rights.
Q:What is the anticipated process for releasing data from the CheMo4METPANC study, and is there potential for accelerated approval based on the study?
A:The interim analysis is prespecified in the protocol, and the timing of publication will depend on discussions with Colombia, as they have the rights to publish first. Accelerated approval is unlikely because the interim analysis is based on PFS, while the standard primary endpoint for approval is overall survival.
Q:What should be expected from the sickle cell study in terms of key metrics and endpoints?
A:Key metrics include safety, mobilization into peripheral blood (cells per microliter), and collection yield. Preliminary results from 7 patients showed promising outcomes, with motixafortide achieving higher mobilization compared to plerixafor. However, manufacturing data will not be available from this study.
Q:What is the status of BioLineRx's efforts to acquire new assets, and what are the characteristics of the assets being targeted?
A:BioLineRx is targeting early clinical stage assets (IND through Phase I) with clear development plans, manageable costs, and transactability. They aim to close a transaction this year and focus on oncology and other areas of expertise. They prefer assets requiring minimal upfront payments.
Q:How was the ASCO data from the pancreatic study received?
A:The ASCO data, particularly the results on liver metastases reduction, was received with excitement and positive feedback.
Q:What are the most attractive sources for pipeline candidates, and how does the current funding environment affect negotiations?
A:The most attractive sources are smaller private companies that lack capital or expertise to advance their assets. Academic institutions are less relevant for clinical stage projects, and big pharma assets are often too costly. The current funding environment gives BioLineRx an advantage in negotiations, as they can offer efficient development capabilities.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear timeline for the publication of interim data from the CheMo4METPANC study, citing the need to discuss timing with Colombia. Additionally, they did not provide specific details about the two assets under consideration for acquisition, such as their therapeutic areas or stages of development.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APHEXDA development
APHEXDA investigator
APHEXDA progress
ASCO patient
BioLineRx member
BioLineRx role
BioLineRx transaction
Co LLC
Conference Instructions
Corporate Participant
Division Conference
Division Justin
ET Vandermosten
FDA
General decrease
Gloria decrease
Hospital utility
Howard Walsh
IIb PDAC
Inc Ladies
Institutional
LLC Research
PDAC study
PFS month
Research Division
Serlin Chief
Zeevi Chief
ability
compensation decrease
decrease headcount
hope
motixafortide monotherapy
revenue cost
right
study motixafortide
BLRX Transcript
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
Unknown5-27
The earnings call reflects financial instability with a net loss and increased R&D expenses, despite a slight revenue increase. The Q&A highlights management's lack of transparency and potential risks in partnerships and supply chains. While there is optimism about market trends and product launches, the financial and operational uncertainties, reliance on preclinical data, and vague responses suggest a negative sentiment, likely leading to a stock price decline.
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
Unknown3-23
The earnings call lacks detailed financial metrics, revenue, or margin updates, leading to uncertainty. The strategic initiatives and market trends are positive, but the absence of explicit guidance and financial details, coupled with acknowledged risks, tempers optimism. The Q&A section does not provide additional clarity, reinforcing a neutral sentiment.
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
Unknown11-24
The earnings call reveals several concerns: delayed revenue from trials, financial dependency on a single product, and limited cash reserves. The Q&A section highlights management's evasiveness on key metrics, further increasing uncertainty. Despite reduced losses and operational cost cuts, the company's reliance on royalties and uncertain trial outcomes are significant risks. These factors suggest a negative sentiment towards the company's short-term stock performance.
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
Unknown8-14
Despite a strong partnership with Ayrmid Pharma and reduced operating costs, the company faces risks such as slow APHEXDA adoption and a significant net loss. The Q&A revealed cautious optimism with positive feedback on ASCO data but uncertainty around asset acquisition and study timelines. The neutral rating reflects balanced prospects, with financial sustainability dependent on future milestones.
BLRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
